Dr. Nitin Y. Bhatt, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 273
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Ohio State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
OH license 35.072012 -
Critical Care Medicine (Internal Medicine) Physician
OH license 35.072012 -
Sleep Medicine (Internal Medicine) Physician
OH license 35.072012
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
- Holzer Clinic LLC (269 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 273
- Services billed
- 618
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 183 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 134 | 67 |
| Test to measure expiratory airflow and volume | 100 | 98 |
| Established patient office or other outpatient visit, 30-39 minutes | 94 | 71 |
| Test to examine how well the lungs exchange gases | 77 | 77 |
| Test to determine lung volumes using sensors | 72 | 72 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 53 |
| Test for exercise-induced lung stress | 33 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 20 | 20 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Columbus, OH | 54 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Columbus, OH | 39 |
| Ofev (nintedanib esylate) | 26 |
| Montelukast Sodium Other prescribers in Columbus, OH | 23 |
| Omeprazole Other prescribers in Columbus, OH | 21 |
| Levalbuterol Tartrate Hfa (levalbuterol tartrate) Other prescribers in Columbus, OH | 21 |
| Mycophenolate Mofetil Other prescribers in Columbus, OH | 19 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Columbus, OH | 18 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Columbus, OH | 16 |
| Armodafinil | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 10 payments worth $9,436 in total to this clinician.
| United Therapeutics Corporation | $9,419 |
|---|---|
| Insmed, Inc. | $17.38 |
| Consulting Fee | $8,200 |
|---|---|
| Travel and Lodging | $936 |
| Food and Beverage | $283 |
| Education | $17.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation Jan 31, 2025 | Consulting Fee TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $8,200 |
| United Therapeutics Corporation Jan 30, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Dallas, TX · in-kind | $567 |
| United Therapeutics Corporation Jan 30, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Dallas, TX · in-kind | $369 |
| Insmed, Inc. Jul 24, 2025 | Education in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $211,161 in research payments for these studies, mostly to the institutions running them.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim International GmbH - PDE4 Phase III trial in IPF patients
Boehringer Ingelheim International GmbH - PDE4 Phase III trial in PF-ILD
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.